This result indicates that the SP-B promoter is active in a subgroup of large cell lung carcinomas, and suggests that the SP-B promoter can be used to target this subgroup at the transcriptional level for future lung cancer therapy. This evidence concerns the gene SFTPB and lung carcinoma.